FDA-approved chemotherapeutic drugs that are capable of inhibiting DNA synthesis, including teniposide, dacarbazine, doxorubicin, and triethylenemelamine, and inhibitors of hypoxia-inducible factor, MCL-1, ribonucleotide reductase, and FASN in clinical trials are potential drugs to treat cancer patients with high YAP1 expression. Here, FASN is linked to cancer.